Phase II study of miltefosine (Hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult— An EORTC Soft Tissue and Bone Sarcoma Group study

The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.